Beyond Air revenue doubles as company offloads autism platform to XTL
Compartilhar
Beyond Air (NASDAQ:XAIR) reported a surge in third-quarter revenue and a strategic pivot toward its core respiratory business, announcing a binding agreement to divest its autism and neuro-oncology subsidiary to XTL Biopharmaceuticals.
